

Amino acids and peptides. LVII. Synthetic peptide with a sequence of ribonuclease from *Sulfolobus solfataricus*, SSR(1–62), does not function as an RNase

Shima Joshi^a, Yuko Tsuda^b, Noriyuki Shintomi^b, Hiroyuki Kondo^b, Yasuhiro Nishiyama^c, Masanori Iwama^d, Kazuko Ohgi^d, Masachika Irie^d, Yoshio Okada^{b,*}

^aSTAR Biochemicals, Torrance, CA 90501-1722, USA

^bKobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan

^cSeikei University, Musashino-shi, Tokyo 180-0001, Japan

^dHoshi College of Pharmacy, Shinagawa-ku, Tokyo 142-8501, Japan

Received 18 October 1999; received in revised form 22 January 2000

Edited by Shozo Yamamoto

Abstract The 62 residue peptide, SSR(1–62), whose sequence corresponds to that of ribonuclease (RNase) from *Sulfolobus solfataricus*, and its related peptides, SSR(1–22) and SSR(10–62), were chemically synthesized and their RNase activity and DNA-binding activity were examined. The RNase activity assay using yeast RNA or tRNA^{fMet} as substrate showed that the synthetic peptide SSR(1–62) did not hydrolyze yeast RNA or tRNA^{fMet}. These data were not consistent with previous reports that both the native peptide isolated from *S. solfataricus* [Fusi et al. (1993) Eur. J. Biochem. 211, 305–311] and the recombinant peptide expressed in *Escherichia coli* [Fusi et al. (1995) Gene 154, 99–103] were able to hydrolyze tRNA^{fMet}. However, the synthetic SSR(1–62) exhibited DNA-binding activity. In the presence of synthetic SSR(1–62), the cleavage of DNA (plasmid pUCRh2-4) by restriction endonuclease (*EcoRI*) was not observed, suggesting that synthetic SSR(1–62) bound to DNA protected DNA from its enzymatic digestion. Neither SSR(1–22) nor SSR(10–62) prevented DNA from being cleaved by a restriction enzyme. These findings strongly suggest the importance of not only the N-terminal region of SSR(1–62) but also the C-terminal region for DNA-binding. Circular dichroism spectroscopy of synthetic SSR(1–62) indicated a β -sheet conformation, in contrast with synthetic SSR(1–22), which exhibited an unordered conformation.

© 2000 Federation of European Biochemical Societies.

Key words: Circular dichroism spectroscopy; DNA-binding activity; P2; RNase activity; Synthetic SSR(1–62); *Sulfolobus solfataricus*

1. Introduction

Ribonuclease (RNase) is an enzyme that catalyzes the hydrolysis of phosphodiester bonds in an RNA chain. More RNases occur in organisms than previously thought. However, little is known about archaeobacterial RNases. Only two RNases P, which are involved in tRNA processing, have been identified and characterized thus far, one from *Sulfolobus solfataricus* and the other from *Haloferax volcanii* [1]. Fusi et al. isolated three proteins with RNase activity, referred to as P1, P2 and P3, from the thermoacidophilic archaeobacterium *S. solfataricus* [2]. Protein P2 consists of 62 amino acid

residues and shows no significant similarity to any known class of RNases; in particular, P2 is deficient in His residues, which are essential for catalysis in all of the RNases known to date. On the other hand, the complete amino acid sequence of P2 revealed a high sequence similarity to that of the 7 kDa DNA-binding proteins [3–5]. In fact, protein P2 and P3 demonstrated non-specific DNA-binding activity [2]. The first question coming from the identification of those proteins is what mechanism is involved when they function as RNases. The second one is which region of the peptide is involved in RNase activity. Furthermore, most surprisingly, it was found that they exhibit two different functions; RNase activity and DNA-binding activity. These questions motivated us to investigate the structure-activity relationship of P2. In our previous study [6,7], attempts were made to synthesize peptide fragments related to SSR(1–62): SSR(57–62), SSR(52–62), SSR(47–62), SSR(44–62), SSR(37–62), SSR(33–62), SSR(27–62) and SSR(17–62) by both solution and solid-phase methods. However, those truncated peptides showed neither RNase activity nor DNA-binding activity, suggesting the importance of the N-terminus region to manifest RNase activity or DNA-binding activity [7]. In this report, we present the chemical synthesis of SSR(1–62), SSR(1–22) and SSR(10–62) and examination of their RNase activity and DNA-binding activity.

2. Materials and methods

2.1. Peptide synthesis and purification

SSR(1–62), SSR(1–22) and SSR(10–62) were synthesized by Boc solid-phase synthesis using Boc-Lys(2-Cl-Z)-Pam-resin or Boc-Val-Pam-resin as the solid support on a Vega automated peptide synthesizer according to the procedure described elsewhere [7]. Cleavage from the resin and deblocking of the protecting groups were achieved with the low-high HF procedure [8]. Briefly, the protected peptide-resins were treated with *p*-thiocresol/*p*-cresol/dimethyl sulfide (DMS)/HF (0.8:3.2:26:10) at –4°C for 2 h. After removal of DMS, HF was again condensed into the reactor. The reaction mixture was kept at –4°C for 1 h. After cleavage and deblocking, the crude peptides were filtered, dried, dissolved in dilute acetic acid and lyophilized. The peptides were purified by preparative high performance liquid chromatography (HPLC) on a C18 column (3.9×150 mm, Waters). The structure of the synthetic peptides was characterized by amino acid analysis and mass spectrometric methods. In the case of SSR(1–62), protein sequencing was performed on an ABI477A protein sequencer.

2.2. Enzyme activity assay

The RNase activity was determined according to the procedure

*Corresponding author. Fax: (81)-78-974 5689.
E-mail: okada@pharm.kobegakuin.ac.jp

RNase activity of bovine pancreatic RNase A under the conditions described in Section 2. To investigate the cleavage condition of yeast RNA better, synthetic peptides were incubated for 5–60 min at 60°C in 50 mM acetate buffer, pH 5.0, or in 50 mM Tris–HCl buffer, pH 7.5. No effect was exerted by reaction time or pH. Also, varying ratios of synthetic peptides to yeast RNA were employed; peptides (10 µg, 20 µg and 50 µg) to yeast RNA (400 µg). The RNase activity of synthetic peptides was unaffected by the ratio to the substrate. Finally, we were not able to find any RNase activity of synthetic peptides under the conditions we used (see Section 2), although the ratio of synthetic peptides (50 µg) to yeast RNA (400 µg) was much higher than when the usual method is employed.

Furthermore, we tried to examine hydrolysis activity of synthetic SSR(1–62) on *tRNA*^{fMet} as mentioned by Fusi et al. [2]. Upon incubation of *tRNA*^{fMet} with synthetic SSR(1–62), no fragment was generated (Fig. 2). We did not observe RNase activity of synthetic peptide(1–62) against yeast RNA or *tRNA*^{fMet}. These results clearly demonstrated that the property of the synthetic SSR(1–62) was enzymatically distinguishable from that of native P2 [2].

3.3. DNA-binding activity of peptides

The DNA-binding activity of SSR(1–62), SSR(1–22) and SSR(10–62) was investigated. SSR(1–62) bound to plasmid DNA pUCRh2-4 causing a significant mobility change in the SSR(1–62)-plasmid DNA complex compared to plasmid DNA alone on 1% agarose gel (Fig. 3, lines 4 and 2, respectively). Dissociation of the SSR(1–62)-plasmid DNA complex by phenol-10 mM Tris–HCl buffer, pH 8.0, containing 1 mM EDTA extraction, released native plasmid DNA which was digested by restriction endonuclease *Eco*RI leading to a fragment DNA with ca. 800 bp (Fig. 3, lines 5 and 3, respectively). Incubation of the SSR(1–62)-plasmid DNA complex with restriction endonuclease *Eco*RI did not lead to the fragment DNA with ca. 800 bp (Fig. 3, line 6). These results showed that SSR(1–62) bound to DNA as the DNA-binding protein P2. In a previous report [7], we demonstrated that SSR(17–62) did not bind to plasmid DNA. In addition to SSR(17–62), SSR(1–22) with deletion of the C-terminal region (23–62) and SSR(10–62) lacking 9 amino acid residues at the N-terminus did not bind to plasmid DNA. When each mixture of peptide and plasmid DNA was incubated with *Eco*RI, it did release the DNA fragment with ca. 800 bp (Fig. 3, lines 15 and 9, respectively). From these results, only SSR(1–62) with a full sequence of P2 had the ability to bind DNA (Table 1).

3.4. Conformational properties of synthetic peptides

The CD spectra of the synthetic peptides were measured (Fig. 4). Synthetic SSR(1–62), the only peptide with DNA-




Fig. 4. CD spectra of synthetic peptides SSR(1–62) (line 1), SSR(10–62) (line 2) and SSR(1–22) (line 3).

binding ability, showed a conformation rich in β -sheet characterized by a peak at 217 nm. The CD spectrum of SSR(1–22) did not exhibit either double minima at 222 nm and 208 nm or a minimum at 217 nm, which characterized the α -helix structure and β -sheet structure, respectively [12]. The dominant structure of SSR(1–22) would be a random coil. The CD spectra of SSR(10–62) are also shown in Fig. 4. Comparison of those spectra indicated that deletion of the N- or C-terminal region produced a conformational change.

4. Discussion

We have succeeded in preparing peptides SSR(1–62), SSR(10–62) and SSR(1–22), by chemical methods. Synthetic SSR(1–62) displayed less than 0.05% of RNase activity of bovine pancreatic RNase A with the same assay method used by Fusi et al. [2,13] and no ability to hydrolyze *tRNA*^{fMet}. Fusi et al. reported that protein P2, not only isolated from the thermoacidophilic archaeobacterium *S. solfataricus* [2] but also expressed from *Escherichia coli* and yeast cells with use of the synthetic P2 encoding gene [14], was able to hydrolyze *tRNA*^{fMet}. Thus, our results conflict with those of Fusi et al. [2,13,14]. The wild-type P2 enzyme was partially methylated at Lys⁴ and Lys⁶, while synthetic P2 was not methylated. However, lysine methylation would not play a role in RNase activity, because recombinant P2 exhibited RNase activity, although the lysine residues of recombinant P2 were probably not methylated. Fusi et al. demonstrated that P2 on gel filtration displayed two peaks, the assessed molecular masses of which were 13.0 and 7.3 kDa, respectively [2]. One possible explanation of the disparity between our results and those of Fusi et al. would be that synthetic SSR(1–62) differed from P2 in quaternary structure so that synthetic SSR(1–62) lacks the properties of RNase. Our results suggest the necessity to investigate further: (i) whether the P2 protein has two stable conformations, only one of which is enzymatically active while the other is inactive, and the chemically synthesized P2 was in an inactive state; (ii) whether the P2 protein isolated from *S. solfataricus* cells and host cells of *E. coli* and *S. cerevisiae* had adsorbed any nucleolytically active protein; (iii) by what mechanism did P2, lacking His residues, hydrolyze RNA when, in fact, His residues are the most common constituents of nucleolytic enzymes.

Although synthetic SSR(1–62) was inactive as an RNase, SSR(1–62) exhibited DNA-binding activity. On the other hand, neither SSR(10–62) nor SSR(1–22) could bind DNA.

Table 1
DNA-binding activity of synthetic SSR(1–62) and SSR-related peptides

	– <i>Eco</i> RI	+ <i>Eco</i> RI	DNA-binding activity ^a
SSR(1–62)	Increased M.w.	Not cleaved	+
SSR(1–22)	Unchanged M.w.	Cleaved	–
SSR(10–62)	Unchanged M.w.	Cleaved	–

^aPlus sign (+) indicates no inhibition of *Eco*RI-binding to DNA. Minus sign (–) indicates inhibition of *Eco*RI-binding to DNA.

This suggests that some part of the N-terminal region might interact with some part of the C-terminal region of SSR(1–62) to form a conformation necessary for DNA-binding.

Acknowledgements: The authors are grateful to Ms. S.D. Bryant of the National Institute of Environmental Health Sciences (NIEHS) for her kind help during the preparation of this manuscript. This work was supported in part by a grant from the Science Research Promotion Fund of the Japanese Private School Promotion Foundation.

References

- [1] Darr, S.C., Brown, J.W. and Pace, N.R. (1992) *Trends Biochem. Sci.* 17, 178–182.
- [2] Fusi, P., Tedeschi, G., Aliverti, A., Ronchi, S., Tortora, P. and Guerritore, A. (1993) *Eur. J. Biochem.* 211, 305–310.
- [3] Kimura, M., Kimura, J., Davie, P., Reinhardt, R. and Dijk, J. (1984) *FEBS Lett.* 176, 176–178.
- [4] Grote, M., Dijk, J. and Reinhardt, R. (1986) *Biochim. Biophys. Acta* 873, 405–413.
- [5] Choli, T., Wittman-Liebold, B. and Reihardt, R. (1988) *J. Biol. Chem.* 263, 7087–7093.
- [6] Okada, Y., Joshi, S., Shintomi, N., Kondo, Y., Tsuda, Y., Ohgi, K. and Irie, M. (1999) *Chem. Pharm. Bull.* 47, 1089–1096.
- [7] Tsuda, Y., Shima, J., Shintomi, N., Kondo, Y., Ohgi, K., Irie, M. and Okada, Y. (1999) *Chem. Pharm. Bull.* 47, 1097–1101.
- [8] Tam, J.P., Heath, W.F. and Merrifield, R.B. (1983) *J. Am. Chem. Soc.* 105, 6442–6455.
- [9] Maniatis, T. and Efstraiadis, A. (1980) in: *Method in Enzymology* (Grossman, L. and Moldave, K., Eds.), Vol. 65, pp. 299–305, Academic Press, New York.
- [10] Morrissey, J.H. (1981) *Anal. Biochem.* 117, 307–310.
- [11] Kulms, D., Schaffer, G. and Hahn, U. (1995) *Biochem. Biophys. Res. Commun.* 214, 646–652.
- [12] Greenfield, N. and Fasman, G.D. (1968) *Biochemistry* 8, 4109–4120.
- [13] Fusi, P., Grisa, M., Tedeschi, G., Nergi, A., Guerritore, A. and Tortora, P. (1995) *FEBS Lett.* 360, 187–190.
- [14] Fusi, P., Grisa, M., Mombelli, E., Consonni, R., Tortora, P. and Vanoni, M. (1995) *Gene* 154, 99–103.